Neovacs, a biotechnology company focused on active immunotherapies for the treatment of autoimmune diseases, has agreed with the Argentinean company Amegabiotech to acquire its Interferon Alpha (IFNalpha) manufacturing license.
Amegabiotech is a global producer of IFNalpha protein and a long term supplier of Neovacs, particularly for its on-going Phase IIb study of IFNalpha Kinoid in Lupus.
IFNalpha is a key component of Neovacs` lead therapeutic candidate, IFNalpha Kinoid, which is composed of inactivated IFNalpha coupled with a carrier protein, keyhole limpet hemocyanin.
Miguel Sieler, CEO of Neovacs, commented: “With this agreement, the company has reinforced its ability to maintain control of its technology, quality control, manufacturing and costs, which is key to our overall growth strategy as we continue advancing the clinical development of our lead candidate IFNalpha Kinoid. With greater control over our Kinoid technology, we can drive optimization of manufacturing costs and more effectively support the potential commercialization of IFNalpha Kinoid for the treatment of lupus, a complex autoimmune disease where medical needs are urgent and unmet today.”